Oscar Health, Inc. (OSCR) Tuesday reported wider loss for the fourth quarter compared to the prior year, despite growth in revenues. The quarterly result was impacted by higher medical operating expenses.
The company now projects improved revenue for full-year 2026, compared to its previous outlook.
Currently, OSCR is up more than 6%, at $13.52.
The quarterly net loss attributable to the firm widened to $352.61 million from $153.55 million a year ago.
On a per-share basis, loss was $1.24 wider than $0.62 in the prior year.
Revenue increased to $2.81 billion from $2.39 billion in the year-ago period.
Total operating expenses were $3.138 bln, up from $2.540 bln last year. Medical operating expenses climbed to $2.620 billion, from $2.065 billion last year.
For the full year, the firm reported loss of $443.15 million, or loss per share of $1.69, compared with profit of $25.43 million, or $0.10 per share, last year.
Adjusted EBITDA loss widened to $279.81 million from $199.23 million in 2024.
Full-year revenue increased to $11.70 billion from $9.18 billion a year ago.
Looking ahead to full-year 2026, the firm expects revenue to be in the range of $18.7 billion to $19.0 billion, up from the $11.70 billion reported to date.
Earnings from operations are projected to be in the range of $250 million to $450 million for the full year 2026.
OSCR has traded between $11.20 and $23.80 in the last year. The stock closed Monday's trade at $12.66, up 3.43%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.